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Abstract
It is a common practice to perform a separate analysis of efficacy and safety
data from clinical trials to estimate the benefit and risk aspects of a particular
treatment regimen. However, by doing so, one is likely to miss the complete
picture of the treatment effect given that these data are generated from the
same study subjects and therefore most likely will be correlated. Therefore, it is
desirable to analyze these data jointly to obtain a more complete profile of the
treatment regimen. A substantial number of statistical methodologies have been
proposed in the last decade to model the time-to-event data and longitudinal
repeated measures jointly. These methods provide better insights to understand
the treatment effect in time-to-event data by incorporating the information
contained in the longitudinal repeated measures. In this article, we utilize the
joint model method to analyze the time-to-event data, such as patient overall
survival, and the repeated measures of laboratory test data to better estimate
the treatment effect of a regimen. The data from a recent oncology clinical trial
is used to illustrate the application of our proposed method.
Keywords: Joint modeling; Time-to-event data; Longitudinal repeated
measures; Controlled clinical trials

Introduction
During the course of a clinical trial, several types of data are
usually collected. This includes data to investigate the efficacy of
the intervention of a test drug, the demographic data of the subjects
under study, the laboratory data to understand the pharmacological
effect of the treatment on the body, and the possible adverse effects,
etc. Conventionally, it is common practice to analyze the efficacy and
safety data separately to estimate the benefit and risk aspects of the
treatment regimen. However, by performing separate analysis, one is
likely to miss the complete picture of the treatment effect given that
these data are generated from the same study subjects and therefore
most likely will be correlated.
For example, in cancer clinical trials to study patient survival
after treatment, patients are usually given treatment which can
substantially cause neutropenia, namely, the reduction of white blood
cells. Severe neutropenia can lead to infection or sepsis which can
in turn lead to other complications that affect patient’s survival. This
indirect treatment effect usually is not captured during the efficacy
analysis alone. Therefore, it is more desirable to analyze these data
together to obtain a more complete profile of the treatment regimen.
Similar strategies have also been implemented in the study of HIV,
neuroscience, and prostate cancers, just to name a few. In the
following, we will focus our attention on the analysis of survival data
and repeated measures of laboratory parameters such as white blood
cell counts and other adverse effects.
A substantial number of statistical methodologies have been
proposed in the last decade to model the time-to-event data and
longitudinal repeated measures jointly. For example, Tsiatis et al.
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[1] in the study of AIDS, Diggle [2] in the study of patients with
schizophrenia symptoms, Henderson, et al. [3] studied the positive
and negative symptom scale in neuroscience, and Law et al. [4] in the
study of disease progression biomarkers, etc.
Using parametric or semi-parametric maximum likelihood or
and Bayesian methods, these authors estimated the parameters for
both the longitudinal and event processes and used the associated
asymptotic properties of the estimates. They also showed that the
estimates from the joint model can usually be more efficient than the
estimates from the separate models.
In this article, we utilize the joint model method to analyze
the patient overall survival incorporating the laboratory data
of neutrophils counts to better estimate the treatment effect
of an experimental cancer therapy. We describe the statistical
methodologies about joint modeling in section 2 followed by the
parameter estimation and model diagnostics in section 3. In section
4, we illustrate the applications of these methods to the data from a
recent cancer drug study. We conclude our paper with discussion in
section 5.

Joint Modeling Methods
Let Ti denote the observed failure time for the i-th subject
(i=1,…,n), which is taken as the minimum of the true event time Ti *
and the censoring time Ci, namely, Ti = min(Ti* ; Ci ) . Furthermore, we
define the event indicator as δ i = I (Ti* < Ci ) , where I(.) is the indicator
function that takes the value 1 if the condition Ti* < Ci is satisfied, and
0 otherwise. Thus, the observed data for the time-to-event outcome
consist of the pairs {(Ti,{(Ti,δi),i=1,…,n}.

Citation: Tsai KT and Peace KE. Joint Modeling of Treatment Effect on Time-to-Event Endpoint and Safety
Covariates in Control Clinical Trial Data Analysis. Austin Biom and Biostat. 2015;2(3): 1025.

Kao-Tai Tsai

Austin Publishing Group

For the longitudinal responses, let yi(t) denote the value of the
longitudinal outcome at time point t for the i-th subject. We should
note here that we do not actually observe yi(t) at all time points,
but only at the very specific occasions tij at which measurements
were taken. Thus, the observed longitudinal data consists of the
measurements yij={yi(tij), j=1,…,ni}.
As in many clinical trials, data could be measured with errors due
to the limitation of instruments and quantifications. That is especially
true for the laboratory data. Therefore, as a general setting, we assume
the following relationship between the observed value yi(t) and the
true underlying unobserved value mi(t):
yi(t) =mi(t)+εi,					

(1)

where εi is the random error following a continuous distribution
function. In the following, we will assume εI follows a normal
distribution for simplicity.
For the event process, we assume the following hazard model:

hi (t | wi ) = h0 (t ) exp{γ wi }, 			
'

(2)

where wi is the vector of covariates. One of our aim is to associate
mi(t) with the event outcome Ti in addition to the vector of covariates
wi to better estimate the endpoints of interest.
To quantify the effect of mi(t) on the risk for an event, a commonly
adopted approach is to use a relative risk model proposed by Therneau
and Grambsch [5]:

hi (t | M i (t ), wi ) = h0 (t ) exp{γ ' wi + α mi (t )},

(3)

where Mi(t)={mi(u),0<u<t) denotes the history of the true unobserved
longitudinal process up to time t, h0(.) denotes the baseline risk
function, and wi is a vector of baseline covariates (such as a treatment
indicator, history of diseases, etc.) with a corresponding vector of
regression coefficients.
In the model above, the parameter α quantifies the effect of the
underlying longitudinal outcome to the risk for an event in an additive
manner; for instance, in the example section below, α measures the
effect of the value of Absolute Neutrophils Counts (ANC) on the risk
for death due to the fact that a low ANC value is likely to lead to
infection which can indirectly cause medical complications to affect
the overall patient survival.
The baseline risk function h0(.) is typically left unspecified.
However, within the joint modeling framework, Hsieh, et al. [6] had
noted that unspecified h0(.) can lead to underestimated standard errors
of the parameter estimates. To avoid this problem, one can specify the
function using the Weibull [7], Gamma, or for more flexible models
in which h0(.) is approximated using step functions or spline-based
approaches. Alternatively, if the proportionality assumption in (2) or
(3) fails, one can use the accelerated failure time model.
In order to incorporate a time dependent covariate within this
framework, we define the survival function So as

{

S0 ~ ∫ exp γ T w + α m( s )} ds, 			
T*

0

(4)

with the corresponding hazard function for subject i being
hi(t|Mi(t),wi)=h0{Vi(t)}exp{Twi+αmi(t)}		
Submit your Manuscript | www.austinpublishinggroup.com

(5)

where
T*

Vi (t ) = ∫ exp{γ T wi + α mi ( s )}ds. 		
0

(6)

An important difference between equations (5) and (3) is that in
the former the entire covariate history Mi (t) is assumed to influence
the subject-specific risk (due to the fact that h0(.) is evaluated at
Vi(t), whereas in the latter the subject-specific risk depends only
on the current value of the time-dependent covariate mi(t). The
survival function for a subject with covariate history Mi(t)} equals
Si{t|Mi(t)}=S0{Vi(t)}, which means that this subject ages on an
accelerated schedule Vi(t) compared to S0.
Equation (1) is a general framework of the relationship between
the observed and true underlying data. The model needs to be
explicitly specified during the data analysis to take into account the
intermittent nature of the data collection. Namely, for subject , one
only observes yij={yi(tij), j=1,…,ni} at a set of time {tij=1,…,ni}.
Assuming the normal error distribution and linear mixed effects
model to describe the subject-specific longitudinal process, we have
yi(tij)= mi(tij)+εi(tij)

= xiT (tij ) β + ziT (tij )bi + ε i (tij ), ε i (tij )~N (0, σ 2 )

(7)

where β denotes the vector of the unknown fixed effects parameters,
bi denotes a vector of random effects, xi(t) and zi(t) denote row vectors
of the design matrices for the fixed and random effects, respectively,
and εi(t) is the measurement error term, which is assumed to be
independent of bi and with mean 0 and variance σ2.
Parameter estimation and model diagnostics
Several estimation methods had been proposed for the joint
modeling, e.g., semiparametric maximum likelihood (Hsieh, et al. [6];
Henderson, et al. [3]; Wulfsohn and Tsiatis [8], Tsiatis and Davidian
[9]) and Bayes methods (Chi and Ibrahim [10]; Brown and Ibrahim
[11]; Wang and Taylor [8]; Xu and Zeger [12]).
Briefly, the maximum likelihood estimation for joint models is
based on the maximization of the likelihood corresponding to the
joint distribution of the time-to-event and longitudinal outcomes
{Ti,δi,yi}. Since the time-independent random effects bi underlies both
the longitudinal and survival processes, assume
with

f (Ti , δ i , yi | bi , θ ) = f (Ti , δ i | bi , θ ) f ( yi | bi , θ )

(8)

f ( yi | bi , θ ) = Π f { yi (tij ) | bi , θ }, 			

(9)

j

where θ = (θt' , θ y' , θb' )' denotes the parameter vector, with θt denoting
the parameters for the event time outcome, θy the parameters for the
longitudinal outcomes, and θb the unique parameters of the randomeffects covariance matrix, and f(.) denotes an appropriate probability
density function for the longitudinal or event process.
Under the modeling assumptions and the conditional
independence assumptions in equation (8), assume f{yi(tij)|(bi,θy}
being the univariate normal density for the longitudinal responses,
and f(bi,θb) being the multivariate normal density for the random
effects, the joint log-likelihood contribution for the i-th subject is
log f (Ti , δ i , yi , θ ) = log ∫ f (Ti , δ i | bi , θi , β )[∏ f { yi (tij ) | bi , θ }] f (bi , θb )dbi ,
j

(10)
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where the likelihood of the event process is
f (Ti , δ i | bi , θt , β ) = {hi (Ti | M i (Ti ), θt , β )}δi Si (Ti | M i (Ti ), θt , β ),
						

(11)

with hi(.) given by either (3) or (5), and

Si (t | M i (t ), wi , θt , β ) = Pr(Ti * > t | M i (t ), wi , θt , β )
t

=exp{-- ∫ hi ( s | M i ( s ), θt , β )ds}. 			
0

(12)

Since the integration in (10) generally has no analytical form, the
maximization of the log-likelihood function (10) with respect to θ is
conventionally performed using numerical integration techniques
such as Gaussian quadrature and Monte Carlo. These approaches
have been successfully applied in the joint modeling framework by
various authors mentioned previously.
Residual plots are the conventional methods for model diagnostics
to verify the appropriateness of the distributional assumptions and
the adequacy of the model assumed. Model diagnostics for linear
mixed model and time-to-event model have been well studied in
the literature. However, given the inter-dependency between the
longitudinal process and the event process, extra cautions are needed
on the diagnostics for the joint model. For example, when a subject
is discontinued the study or died, the data for either process will no
longer be available.
When the process of subject discontinuation is random,
the residuals may be less affected than the scenarios when the
discontinuation was influenced by the failure of treatment and causes
informative missing data issues. Rizopoulos, et al. [13] proposed
a method to augment the observed data with randomly imputed
longitudinal responses. Briefly, based on the parameter estimates
of the joint model with available data, they performed multiple
imputation with repeated sampling from the posterior distribution
of the missing observations given the observed data. The complete
profile of the longitudinal data can thus be established for each
subject. The advantage of using the simulated values together with
the observed data to calculate residuals is that these residuals inherit
now the properties of the complete data model, and therefore they
can be directly used in diagnostic plots.
Example

Figure 1: Box-Cox transformation of ANC values.

effects. Since the LME model requires the normality assumption, data
was transformed using the Box-Cox power function to conform to
the normality assumption. The normal plot after the transformation
is shown in Figure 1.
A total of 455 patients were randomized into two treatment
groups (Group 1 and Group 3) in approximately 2:1 ratio with 204
events of disease progression and a total of 1745 repeated measures of
ANC at the end of the study. Some patients had missing measures of
the ANC during the duration of the clinical study. The patterns of the
ANC values during the visits for each study are shown in Figure 2 and
Figure 3, respectively. The boxplots for the treatments by visits are
also shown in Figure 4. One can easily see substantial ANC values by
treatment interactions during the course of the study. Therefore, we
postulate a model for the longitudinal data to include the treatment,
visit, and their interaction effects.
The Kaplan-Meier curves of survival times for the treatment groups
is displayed in Figure 5. As common practice, a Cox proportional
model was utilized to analyze the event data. Prior to performing the
modeling, the assumption of proportionality was tested and the result
is shown in Figure 6. The proportionality assumption on treatment
effect seems to be reasonable judging from the graph.

In this section, we present an example from a recent clinical
trial to illustrate the use of the procedures described above. This is
a multicenter clinical trial to investigate the treatment effect of an
experimental medicine on breast cancer. Patients were randomized
into two groups, treatment and placebo, to study the treatment
benefit in disease progression. During the trial, the patients’
laboratory data on Absolute Neutrophils Counts (ANC) were also
collected at each treatment visit to monitor the level of neutrophils.
Low level of neutrophiles can possibly cause infection and lead to
other complications to affect the patient disease. Even though the
primary endpoint of the study is the treatment effect on disease
progression which is usually estimated using efficacy data only, it is
more informative to understand how the safety aspects of the study
can also contribute to the patient’s disease progression.
The longitudinal ANC data was analyzed using a linear mixed
effect model with a random intercept and fixed treatment and visit
Submit your Manuscript | www.austinpublishinggroup.com

Figure 2: ANC level of Group 1.

Austin Biom and Biostat 2(3): id1025 (2015) - Page - 03

Kao-Tai Tsai

Figure 3: ANC level of Group 3.

Austin Publishing Group

Figure 6: Proportional hazard test for treatment.
Table 1: LME model of ANC with interaction.
Covariate

Value

Std.Error

DF

t-value

p-value

(Intercept)

1.5961

0.0463

1288

34.419

0.000

trt3

-0.1341

0.0801

453

-1.673

0.095

visit

-0.1520

0.0069

1288

-21.821

0.000

trt3:visit

0.0824

0.0120

1288

6.820

0.000

Table 2: Estimate of cox proportional hazard model.
Covariate

coef

exp(coef)

se(coef)

z

Pr(>|Z|)

trt3

0.5869

1.7983

0.1443

4.068

4.74e-05

Table 3: Estimates of the longitudinal process.
Covariate

Figure 4: ANC values by treatment and visit.

Value

Std.Err

z-value

p-value

(Intercept)

1.6008

0.0460

34.7970

< 0.0001

trt3

-0.1312

0.0809

-1.6207

0.1051

visit

-0.1515

0.0071

-21.3088

< 0.0001

trt3:visit

0.0803

0.0127

6.3020

< 0.0001

Table 4: Estimates of the event process.
Covariate

Value

Std.Err

z-value

p-value

trt3

0.7340

0.2544

2.8855

0.0039

α

-0.0380

0.0534

-0.7112

0.4769

Similarly, the estimate from Cox proportional hazard model with
treatment as covariate indicates a highly significant treatment effect
as shown in Table 2.
After the separate LME model on the longitudinal data of ANC
values and Cox proportional hazard model on the event data was
fitted, a joint model was fitted using MLE to both the longitudinal
and event sub-models and the results are shown in Tables 3 & 4.

Figure 5: Kaplan-Meier curve of patient survival data.

The REML estimates of the mixed effect model with fixed
treatment, visit, treatment by visit interaction effects and random
intercept are shown in Table 1. The results indicate both significant
visit and interaction effects on the values of ANC.
Submit your Manuscript | www.austinpublishinggroup.com

The treatment effect (0.734) in Table 4 from the joint model is
larger than that in Table 2 (0.586) from the Cox model alone. The
value of α in Table 4 has a negative value which reduces the hazard for
the patients with higher values of ANC, even though the effect of α did
not reach the 5% significance level. Putting these findings together,
one can conclude that the treatment effect on ANC indirectly affected
patient survival. This incremental treatment would not have been
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Figure 7: Comparison of random effects between groups.

Figure 9: Comparison of random effects between groups.

Discussion
Medical intervention can usually produce effects in more than
one aspect. They can be direct effect, such as patient survival in our
example, which can be measured directly. They can also be indirect
effects, such as the changes of ANC values in our example, which were
affected by treatment and, in turn, affect the outcomes of interest such
as patient survival. The joint analysis of direct and indirect effects
to assess the intervention efficacy has been well demonstrated in
psychiatric research and other related scientific areas. In other words,
to better understand the complete profile of the treatment effects,
data needs to be analyzed in more than one aspect.

Figure 8: Comparison of random effects between groups.

detected if one were to analyze the treatment efficacy using only the
survival data without bringing in the effect from ANC.
To assess the goodness of fit of the proposed model and better
understand the differences between the treatment groups, we
examined the difference of the random intercepts and the residuals
from the fitted model for the groups. The random intercepts for
the groups were plotted using a Q-Q plot as shown in Figure 7. The
distributions appear to be similar between these two groups with a
minor difference in locations; however, this difference does not seem
to be significant.




The subject-specific residuals (ri (t ij ) = yi (tij ) − xi (tij ) β − zi (tij ) bi )
and marginal residuals (ri = yi − xi β ) were plotted against the
respective fitted values (Figures 8 and 9). The residuals did not seem
to have any obvious pattern to suspect a lack-of-fit of the proposed
model except for a minor dip in the left hand side of the subjectspecific residual plot. This could possibly due to the early dropouts of
some patients who had severe disease at the entry of the clinical study.
An imputation to ‘re-create’ the missing longitudinal data for these
scenarios was conducted and the residual plot after the imputation
seems to alleviate this downward dip to a few degrees but without
substantial difference.

Submit your Manuscript | www.austinpublishinggroup.com

It is a common practice in clinical trials to estimate the treatment
effect using the efficacy data, with a limited number of covariates,
because that is a most direct and conventional approach to gauge
the effect. However, this kind of limited data analysis can sometimes
miss the more complete picture of how the treatment really works. In
conventional clinical trial data analysis, efficacy and safety data are
usually analyzed separately. However, as we have shown in this article,
joint analysis of these variables can reveal extra information about the
treatment and lead to a better understanding of the treatment effect,
which cannot usually be shown by the separate analysis.
Statistical methodologies in joint modeling analysis of
longitudinal and event data has been an area of active research.
Likelihood and Bayes methods to estimate the model parameters have
both been proposed to address the mixed effects with measurement
errors. Parametric and semi-parametric methods have also been
proposed to test various hypotheses. By taking advantage of these
existing methods, one can obtain a more comprehensive profile of
the treatment effects.
In this paper, we only address the continuous longitudinal data
with linear mixed effect models; however, similar research can also
be carried out to incorporate other clinical data which is discrete in
nature such as the disease severity or patient’s physical functioning
ability. In addition, the joint model methods can also be extended
to address the issues of multiple endpoints in clinical trials and
patient population heterogeneity so that the medical practice can be
Austin Biom and Biostat 2(3): id1025 (2015) - Page - 05
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individualized to achieve optimal treatment effect. These topics and
the potential proposals for analysis will be the focus of our continuing
research.
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